Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Revenue (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Revenue for 12 consecutive years, with $6.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue fell 82.16% year-over-year to $6.0 million, compared with a TTM value of $113.6 million through Sep 2025, down 10.26%, and an annual FY2024 reading of $138.1 million, up 36.45% over the prior year.
  • Revenue was $6.0 million for Q3 2025 at CytomX Therapeutics, down from $18.7 million in the prior quarter.
  • Across five years, Revenue topped out at $50.9 million in Q1 2025 and bottomed at $946000.0 in Q4 2022.
  • Average Revenue over 5 years is $20.8 million, with a median of $18.7 million recorded in 2025.
  • The sharpest move saw Revenue crashed 91.5% in 2022, then surged 2712.58% in 2023.
  • Year by year, Revenue stood at $11.1 million in 2021, then plummeted by 91.5% to $946000.0 in 2022, then soared by 2712.58% to $26.6 million in 2023, then skyrocketed by 43.17% to $38.1 million in 2024, then tumbled by 84.35% to $6.0 million in 2025.
  • Business Quant data shows Revenue for CTMX at $6.0 million in Q3 2025, $18.7 million in Q2 2025, and $50.9 million in Q1 2025.